Subscribe to news

Press Center

19.09.2012
On September 18, 2012, a meeting was held at Skolkovo on issues concerning the innovative development of the healthcare sector in Russia.
09.08.2012
August 3 Moscow Bank of Sberbank of Russia and OJSC HSCI - completed the signing of the financing agreements of $ 75 million.
07.08.2012
OJSC HSCI, today announced its unaudited results for the first half of 2012 in accordance with the Russian Accounting Standards (RAS).
06.08.2012
OJSC HSCI, today announced its audited consolidated financial results for the full year ended December 31, 2011 in accordance with International Financial Reporting Standards (IFRS).
20.07.2012
On June 30, 2012, at the 23rd Annual Conference of the Russian Society of Angiologists and Vascular Surgeons in St. Petersburg, a presentation was made of Russia’s first gene-therapy drug Neovasculgen®, developed by the Russian biotech company the Human Stem Cells Institute (HSCI).
22.06.2012
OJSC HSCI, one of Russia’s leading biotech companies (hereinafter – the Company), announces the results of the Annual General Shareholders’ Meeting (AGM) held on June 21, 2012, in Moscow.
01.06.2012
On May 24 the Federal Service for Supervision of Healthcare and Social Development of the Russian Federation (Roszdravnadzor) issued the Human Stem Cells Institute marketing authorization (Registration Certificate No. FSZ 2012/12193) for a device called Celution 800 System, a closed system which processes human adipose (fat) tissue. The apparatus is manufactured by the US-based Cytori Therapeutiсs. The beginning of sales planned for the third quarter of 2012.
21.05.2012
OJSC HSCI, one of Russia’s leading biotech companies, today announced the decision of the Company’s Board of Directors on the agenda of the Annual General Shareholders’ Meeting on the results of 2011.
04.05.2012
OJSC HSCI – The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies, today announces its unaudited results for the first quarter of 2012 in accordance with the Russian Accounting Standards (RAS).
28.04.2012
OJSC HSCI – The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies, today announced the decision of the Company’s Board of Directors on convocation of the Annual General Shareholders’ Meeting upon the results of 2011.